KLTO, KLTOW · CIK 0001907223 · operating
Klotho Neurosciences, Inc. is a biotechnology company developing gene therapy candidates targeting cancer, cardiovascular disease, and neurodegenerative disorders. The company's clinical pipeline includes KLTO-101, a gene therapy product for Alzheimer's disease treatment and prevention, and KLTO-202, designed for Lou Gehrig's disease (amyotrophic lateral sclerosis) treatment and prevention. The company rebranded from Anew Medical, Inc. to Klotho Neurosciences in September 2024.
The company operates as a pre-commercial stage biotechnology firm with no disclosed revenue streams, focusing resources on research and development of its therapeutic candidates. Klotho Neurosciences maintains operations in Omaha, Nebraska, with a minimal workforce of three full-time employees as of the available reporting period.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.32 | $-0.32 | — | |
| 2023 | — | — | — | |
| 2022 | — | — | — |